Fortress Biotech, Inc. - Common Stock (NQ:FBIO)

1.860 -0.130 (-6.53%)

Delayed Quote Updated: 12:50 PM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fortress Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 21, 2023

Via Benzinga

Why Tattooed Chef Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket ↗

July 03, 2023

Gainers Micromobility.com Inc. (NASDAQ: MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

June 01, 2023

It's time to start the day with a breakdown of the biggest pre-market stock movers that traders need to know about for Thursday morning!

Via InvestorPlace

Fortress Biotech's Earnings: A Preview ↗

May 25, 2023

Via Benzinga

Fortress Biotech: Q2 Earnings Insights ↗

August 11, 2022

Fortress Biotech (NASDAQ:FBIO) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Fortress Biotech Q4 Earnings ↗

March 28, 2022

Fortress Biotech (NASDAQ:FBIO) reported its Q4 earnings results on Monday, March 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For May 26, 2023 ↗

May 26, 2023

Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earnings for its first quarter.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 18, 2023

Via Benzinga

Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 18, 2023

Gainers CaliberCos Inc. (NASDAQ: CWD) shares jumped 65.6% to $9.94 amid post-IPO volatility.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 31, 2023

It's time for another dive into the biggest pre-market stock movers with all the hot topics traders need to know about on Friday!

Via InvestorPlace

Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 27, 2023

Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 27, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 14, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 21, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 23, 2022

OnFriday, 143 stocks hit new 52-week lows.

Via Benzinga

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

October 06, 2022

By Rachael Green, Benzinga

Via News Direct

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

October 06, 2022

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner...

Via TheNewswire.com

Fortress Bio's Portfolio Of Marketed Drugs Could Soon See Three Additions ↗

October 05, 2022

Via Benzinga

Fortress Biotech Earnings Perspective: Return On Capital Employed ↗

September 08, 2022

Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q2 sales of $18.89 million. Earnings fell to a loss of $53.93 million, resulting in a 9.0% decrease from last quarter.

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022 ↗

August 04, 2022

Upgrades

Via Benzinga

B. Riley Securities Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know ↗

July 14, 2022

B. Riley Securities has decided to maintain its Buy rating of Fortress Biotech (NASDAQ:FBIO) and lower its price target from $8.00 to $6.00. Shares of Fortress Biotech are trading down 1.01% over the...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 06, 2022

Gainers

Via Benzinga

Looking Into Fortress Biotech's Return On Capital Employed ↗

March 29, 2022

Benzinga Pro data, Fortress Biotech (NASDAQ:FBIO) reported Q4 sales of $18.28 million. Earnings fell to a loss of $68.51 million, resulting in a 49.38% decrease from last quarter.

Via Benzinga

36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

May 16, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public...

From MicroCap Rodeo

Via AccessWire

Fortress Biotech, Inc. (NASDAQ: FBIO) Featured in Virtual Coverage of the 34th Annual Roth Conference

March 16, 2022

Via Investor Brand Network

Benzinga Announces This Week's All Access Guests ↗

February 10, 2022

Benzinga is thrilled to announce the guest lineup for our next All Access show, sponsored by TiiCKER, set to air Friday, February 11 at 9:15 am ET. The Lineup 9:15 am...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 02, 2022

Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.